News provided by
GNT Biotech & Medicals Corporation
12:00 ET
Share this article
TAIPEI, Taiwan, June 21, 2018 /PRNewswire/ -- GNT Biotech & Medicals Co., Ltd. (GNTbm, TPEx Emerging: 7427) announced that it has awarded exclusive sales and marketing rights in Taiwan of anticancer drug Chidamide to pharmaceutical distribution company Taiwan Specialty Pharma Corp. (TSPC) for two indications; hormone receptor-positive, HER-2 negative late stage breast cancer in post-menopausal patients; and peripheral T-cell lymphoma (PTCL). The licensing agreement includes upfront and milestone payments of up to NT$30 million (approx US$1mil), with royalties from sales to be awarded separately.
https://www.prnewswire.com/news-releases/gntbm-announces-licensing-of-exclusive-salesmarketing-rights-of-anticancer-drug-chidamide-to-taiwan-specialty-pharma-corp-tspc-300670155.html